Self-Assembling Peptide for Localized Mast Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective means to specifically activate mast cells for localized treatment of bacterial infections and wound healing, as traditional activation methods can have systemic side effects and limited control over mast cell response.
Innovation Solution
Development of bioactive self-assembling peptides, specifically (RADA)4-GG-(PAMP-12), which form nanofibers and hydrogels that act as scaffolds to locally activate mast cells by incorporating PAMP-12, a MrgX2 agonist, allowing controlled degranulation and tissue-specific immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional mast cell activation methods are used, then mast cells can be activated, but systemic side effects occur and control over mast cell response is limited
Solution Approach 1:
The patent applies local quality by designing a peptide system where activation capability and self-assembly capability are separated into different domains. The MrgX2 agonist domain provides localized activation only where the peptide accumulates, while the self-assembling domain creates localized nanofiber structures. This ensures mast cells are activated only at the application site without systemic effects.
Solution Approach 2:
The self-assembling peptide acts as an intermediary carrier that delivers the MrgX2 agonist specifically to mast cells. The nanofiber structure formed by self-assembly serves as a localized reservoir that releases the agonist in a controlled manner, mediating between the applied material and the mast cell activation process.
2Reliability
If self-assembling peptides are used to form nanofibers and hydrogels, then localized mast cell activation is achieved, but device complexity increases
Solution Approach 1:
The peptide is segmented into functionally distinct domains: an N-terminal self-assembling domain and a C-terminal MrgX2 agonist domain. This segmentation allows each domain to perform its specific function independently while being part of a unified peptide structure, simplifying the overall design compared to using separate components.
Solution Approach 2:
The patent merges two separate functions (self-assembly and mast cell activation) into a single peptide molecule. The self-assembling peptide and MrgX2 agonist are combined in one sequence, creating a dual-functional molecule that reduces the number of separate components needed in the system.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bioactive peptides induce mast cell degranulation in a dose-dependent manner, promoting localized immune response and tissue repair, reducing systemic side effects and enhancing wound healing and bacterial infection treatment efficacy.
Implementation Method 1
a first peptide comprising a self-assembling peptide that mediates self-assembly
Implementation Method 2
a second peptide comprising a MrgX2 agonist
Data Source
AI summary
The present disclosure relates to bioactive self-assembling peptides, nanofibers and hydrogels for activating human mast cells. The peptides, nanofibers and hydrogels comprise a self-assembling peptide that mediates self-assembly linked to a MrgX2 agonist peptide; for example, (RADA)4 linked to proadrenomedullin-12 (PAMP-12).